rimonabant 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
cannabinoid receptors antagonists 4150 168273-06-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • SR141716A
  • rimonabant
  • acomplia
  • SR141716
A pyrazole and piperidine derivative that acts as a selective cannabinoid type-1 receptor (CB1 RECEPTOR) antagonist. It inhibits the proliferation and maturation of ADIPOCYTES, improves lipid and glucose metabolism, and regulates food intake and energy balance. It is used in the management of OBESITY.
  • Molecular weight: 463.79
  • Formula: C22H21Cl3N4O
  • CLOGP: 6.12
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 1
  • TPSA: 50.16
  • ALOGS: -5.36
  • ROTB: 4

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

None

Approvals:

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Drug Use | Suggest Off label Use Form| |View source of the data|




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

External reference:

Pharmaceutical products:

None

rimonabant